New drug combo aims to supercharge immune system to fight cancer before surgery
NCT ID NCT06980038
Summary
This study is testing if adding a new immune-boosting drug (CDX-1140) to an existing immunotherapy (cemiplimab) works better before surgery for advanced head and neck cancer. The goal is to shrink the tumor more effectively, which could lead to less extensive surgery. About 44 patients with stage III or IV cancer will be randomly assigned to receive either the two-drug combination or the single drug alone before their planned operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
RECRUITINGOrange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
RECRUITINGIrvine, California, 92612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
VCU Massey Comprehensive Cancer Center
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.